A Study to Evaluate Remicade (Infliximab) in Moderate-to-Severe Chronic Plaque Psoriasis in the Middle Eastern Population (Study P04528)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
Principal Investigators are NOT employed by the organization sponsoring the study.
There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts
the PI's rights to discuss or publish trial results after the trial is completed.
The PI agrees not to publish/publicly present any interim results of the Study without prior written consent of Sponsor. The PI further agrees to
provide 30 days written notice to Sponsor prior to submission for publication/presentation to allow Sponsor to review materials which report any results of the Study. Sponsor shall have the right to review/comment on
any presentation, which include editorial rights to ensure protection of confidential information, accuracy, and fair balance.
Results Point of Contact
Name/Title:Senior Vice President, Global Clinical Development